Serum and Saliva Concentrations of Sulfamethoxazole and Trimethoprim in Adults and Children: Relation between Saliva Concentrations and in Vitro Activity against Nasopharyngeal Pathogens
- 28 February 1983
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 15 (1) , 107-113
- https://doi.org/10.3109/inf.1983.15.issue-1.18
Abstract
The combination sulfamethoxazole/trimethoprim (SMX/TMP) was given orally to 4 healthy adult volunteers in mean daily doses of 23.0/4.6 mg/kg body weight for 6 days. The serum and saliva concentrations of the drugs were assayed on days 1, 3 and 6. On the first day (0–12 h) there was no measurable concentration of SMX in the saliva. On days 3 and 6 the mean peak levels of SMX in saliva were 7.8 and 9.8 μg/ml, i.e. 8–9% of the corresponding mean peak serum levels. In contrast, the concentrations of TMP in saliva were more than twice as high as those in serum. The mean SMX/TMP ratios in saliva days 3 and 6 were 1.3 and 1.4, respectively, i.e. approximately one-twentieth of the mean SMX/TMP ratios in serum. SMX/TMP was also administered to children with serous otitis media. The drug concentrations in saliva were assayed 2–3 h after administration on days 6 and 9 of a 10-day course, with a mean daily dose of 34.5/6.9 mg/kg body weight. The mean saliva concentration of SMX in the children was slightly higher than in adults and the mean TMP concentration about half of that in adults. The mean SMX/TMP ratio in the children's saliva was 4.2. The in vitro activity of SMX/TMP 20:1 and 4:1 was determined against H. influenzae, D. pneumoniae, B. catarrhalis and group A streptococci. H. influenzae, D. pneumoniae and group A streptococci were found more susceptible to TMP than to SMX, while the reverse was true for B. catarrhalis. In the 3 former, the potentiation of SMX by TMP was more pronounced than was the potentiation of TMP by SMX, while the opposite was recorded for B. catarrhalis. The most beneficial effect of the SMX/TMP combination against nasopharyngeal pathogens was recorded for B. catarrhalis and the weakest effect for H. influenzae and group A streptococci. With the exception of B. catarrhalis, the administration of TMP alone to adults may be just as effective against nasopharyngeal pathogens as is the SMX/TMP combination in children.This publication has 14 references indexed in Scilit:
- Branhamella catarrhalis: antibiotic susceptibility and β-lactamase productionJournal of Antimicrobial Chemotherapy, 1981
- Tissue penetration of trimethoprim and sulphonamidesJournal of Antimicrobial Chemotherapy, 1979
- Minimum Bactericidal Concentration of Sulfamethoxazole-Trimethoprim for Haemophilus influenzae : Correlation with ProphylaxisAntimicrobial Agents and Chemotherapy, 1978
- Rapid Detection of Ampicillin-Resistant Haemophilus influenzae and Their Susceptibility to Sixteen AntibioticsAntimicrobial Agents and Chemotherapy, 1975
- Trimethoprim-Sulfamethoxazole: Absorption, Excretion, and Toxicity in Six ChildrenThe Journal of Infectious Diseases, 1973
- Antimicrobial substances in saliva: sulphamethoxazole and trimethoprim (co-trimoxazole)British Journal of Oral Surgery, 1973
- Trimethoprim in Human Saliva, Bronchial Secretion and Lung TissueActa Pharmacologica et Toxicologica, 1973
- Prediction of Antimeningococcic Chemoprophylactic EfficacyThe Journal of Infectious Diseases, 1971
- Distribution of Diplococcus Pneumoniae Types in Acute Otitis Media in Children and Influence of the Types on the Clinical Course in Penicillin V TherapyScandinavian Journal of Infectious Diseases, 1970
- The determination of sulphanilamide and its derivativesBiochemical Journal, 1941